These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 23458421)

  • 1. Evaluation of specific humoral immune response and cross reactivity against Mycobacterium tuberculosis antigens induced in mice immunized with liposomes composed of total lipids extracted from Mycobacterium smegmatis.
    de los Angeles García M; Borrero R; Marrón R; Lanio ME; Canet L; Otero O; Kadir R; Suraiya S; Zayas C; López Y; Nor Norazmi M; Sarmiento ME; Acosta A
    BMC Immunol; 2013; 14 Suppl 1(Suppl 1):S11. PubMed ID: 23458421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the humoral immune response and cross reactivity against Mycobacterium tuberculosis of mice immunized with liposomes containing glycolipids of Mycobacterium smegmatis.
    Borrero R; García Mde L; Canet L; Zayas C; Reyes F; Prieto JL; Infante JF; Lanio ME; Kadir R; López Y; Sarmiento ME; Nor Norazmi M; Acosta A
    BMC Immunol; 2013; 14 Suppl 1(Suppl 1):S13. PubMed ID: 23458474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteoliposomes from Mycobacterium smegmatis induce immune cross-reactivity against Mycobacterium tuberculosis antigens in mice.
    Rodriguez L; Tirado Y; Reyes F; Puig A; Kadir R; Borrero R; Fernandez S; Reyes G; Alvarez N; Garcia MA; Sarmiento ME; Norazmi MN; Perez Quinoy JL; Acosta A
    Vaccine; 2011 Aug; 29(37):6236-41. PubMed ID: 21736914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and cross-reactivity against Mycobacterium tuberculosis of proteoliposomes derived from Mycobacterium bovis BCG.
    Reyes F; Tirado Y; Puig A; Borrero R; Reyes G; Fernández S; Pérez JL; Kadir R; Zayas C; Norazmi MN; Sarmiento ME; Acosta A
    BMC Immunol; 2013; 14 Suppl 1(Suppl 1):S7. PubMed ID: 23458692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective effect of a lipid-based preparation from Mycobacterium smegmatis in a murine model of progressive pulmonary tuberculosis.
    García Mde L; Borrero R; Lanio ME; Tirado Y; Alvarez N; Puig A; Aguilar A; Canet L; Mata Espinoza D; Barrios Payán J; Sarmiento ME; Hernández-Pando R; Norazmi MN; Acosta A
    Biomed Res Int; 2014; 2014():273129. PubMed ID: 25548767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular and humoral immunogenicity of recombinant Mycobacterium smegmatis expressing Ag85B epitopes in mice.
    Kadir NA; Sarmiento ME; Acosta A; Norazmi MN
    Int J Mycobacteriol; 2016 Mar; 5(1):7-13. PubMed ID: 26927984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective capacity of proteoliposomes from Mycobacterium bovis BCG in a mouse model of tuberculosis.
    Tirado Y; Puig A; Alvarez N; Borrero R; Aguilar A; Camacho F; Reyes F; Fernández S; Pérez JL; Espinoza DM; Payán JA; Sarmiento ME; Norazmi MN; Hernández-Pando R; Acosta A
    Hum Vaccin Immunother; 2015; 11(3):657-61. PubMed ID: 25671612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant Mycobacterium smegmatis expressing an ESAT6-CFP10 fusion protein induces anti-mycobacterial immune responses and protects against Mycobacterium tuberculosis challenge in mice.
    Zhang H; Peng P; Miao S; Zhao Y; Mao F; Wang L; Bai Y; Xu Z; Wei S; Shi C
    Scand J Immunol; 2010 Oct; 72(4):349-57. PubMed ID: 20883320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and protective efficacy of DMT liposome-adjuvanted tuberculosis subunit CTT3H vaccine.
    Teng X; Tian M; Li J; Tan S; Yuan X; Yu Q; Jing Y; Zhang Z; Yue T; Zhou L; Fan X
    Hum Vaccin Immunother; 2015; 11(6):1456-64. PubMed ID: 25905680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved CD4⁺ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial.
    Leroux-Roels I; Forgus S; De Boever F; Clement F; Demoitié MA; Mettens P; Moris P; Ledent E; Leroux-Roels G; Ofori-Anyinam O;
    Vaccine; 2013 Apr; 31(17):2196-206. PubMed ID: 22643213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microstructured liposome subunit vaccines reduce lung inflammation and bacterial load after Mycobacterium tuberculosis infection.
    Trentini MM; de Oliveira FM; Gaeti MP; Batista AC; Lima EM; Kipnis A; Junqueira-Kipnis AP
    Vaccine; 2014 Jul; 32(34):4324-32. PubMed ID: 24951861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The mc2-CMX vaccine induces an enhanced immune response against Mycobacterium tuberculosis compared to Bacillus Calmette-Guérin but with similar lung inflammatory effects.
    Oliveira FM; Trentini MM; Junqueira-Kipnis AP; Kipnis A
    Mem Inst Oswaldo Cruz; 2016 Apr; 111(4):223-31. PubMed ID: 27074251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aerosol immunization by alginate coated mycobacterium (BCG/MIP) particles provide enhanced immune response and protective efficacy than aerosol of plain mycobacterium against M.tb. H37Rv infection in mice.
    Nagpal PS; Kesarwani A; Sahu P; Upadhyay P
    BMC Infect Dis; 2019 Jul; 19(1):568. PubMed ID: 31262260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineering Mycobacteria for the Production of Self-Assembling Biopolyesters Displaying Mycobacterial Antigens for Use as a Tuberculosis Vaccine.
    Lee JW; Parlane NA; Rehm BHA; Buddle BM; Heiser A
    Appl Environ Microbiol; 2017 Mar; 83(5):. PubMed ID: 28087528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of antimycobacterial Th1-cell responses by a Mycobacterium bovis BCG prime-protein boost vaccination strategy.
    Lu M; Xia ZY; Bao L
    Cell Immunol; 2013; 285(1-2):111-7. PubMed ID: 24177251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Mycobacterium tuberculosis-specific subunit vaccine that provides synergistic immunity upon co-administration with Bacillus Calmette-Guérin.
    Woodworth JS; Clemmensen HS; Battey H; Dijkman K; Lindenstrøm T; Laureano RS; Taplitz R; Morgan J; Aagaard C; Rosenkrands I; Lindestam Arlehamn CS; Andersen P; Mortensen R
    Nat Commun; 2021 Nov; 12(1):6658. PubMed ID: 34795205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Future Path Toward TB Vaccine Development: Boosting BCG or Re-educating by a New Subunit Vaccine.
    Gupta N; Garg S; Vedi S; Kunimoto DY; Kumar R; Agrawal B
    Front Immunol; 2018; 9():2371. PubMed ID: 30386336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new tool for tuberculosis vaccine screening: Ex vivo Mycobacterial Growth Inhibition Assay indicates BCG-mediated protection in a murine model of tuberculosis.
    Zelmer A; Tanner R; Stylianou E; Damelang T; Morris S; Izzo A; Williams A; Sharpe S; Pepponi I; Walker B; Hokey DA; McShane H; Brennan M; Fletcher H
    BMC Infect Dis; 2016 Aug; 16():412. PubMed ID: 27519524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ag85b/ESAT6-CFP10 adjuvanted with aluminum/poly-IC effectively protects guinea pigs from latent mycobacterium tuberculosis infection.
    Wang C; Lu J; Du W; Wang G; Li X; Shen X; Su C; Yang L; Chen B; Wang J; Xu M
    Vaccine; 2019 Jul; 37(32):4477-4484. PubMed ID: 31266673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiation of Th1-Type Immune Responses to
    Ko A; Wui SR; Ryu JI; Lee YJ; Hien DTT; Rhee I; Shin SJ; Park SA; Kim KS; Cho YJ; Lee NG
    J Microbiol Biotechnol; 2018 Jan; 28(1):136-144. PubMed ID: 29081214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.